Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04571658 · ClinicalTrials.gov registry record · NA
NEPTUNE Match Study
A NA study of Focal Segmental Glomerulosclerosis and Minimal Change Disease, sponsored by University of Michigan.
- Recruiting
- Registry status
- NA
- Development phase
- 375
- Enrollment target
- 16
- Study locations
NCT04571658: Recruiting NA study of Focal Segmental Glomerulosclerosis and Minimal Change Disease, sponsored by University of Michigan.
NCT04571658 is a NA study of Focal Segmental Glomerulosclerosis and Minimal Change Disease that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 375 participants, above the 217-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (73% higher). The trial reports 16 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04571658, a NA study of Focal Segmental Glomerulosclerosis and Minimal Change Disease, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- NA
- Development phase
- 375 participants
- Enrollment target
- 16
- Study locations
Study Summary
NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.
Primary Outcome
Proportion of NEPTUNE Match participants with at least one matching clinical trial, defined as receiving a Molecular Nephrology Board (MNB) assessment that provides a match to at least one targeted therapy in an ongoing clinical trial
Conditions Studied
Interventions
- OTHER Communication
Study Locations (16)
Washington
- Seattle Children's Hospital - Seattle
- University of Washington Medical Center - Seattle
- Providence Sacred Heart Medical Center - Spokane
New York
- Northwell/Cohen's Children's Hospital - New Hyde Park
- Columbia University Medical Center - New York
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
- Temple University - Philadelphia
Georgia
- Emory University Hospital - Children's Hospital of Atlanta - Atlanta
Illinois
- John H. Stroger, Jr., Hospital of Cook County - Chicago
Kansas
- University of Kansas Medical Center - Kansas City
Maryland
- Johns Hopkins Medicine - Baltimore
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2022-05-02 |
| Est. Completion | 2029-06-30 |
| Phase | NA |
What NCT04571658 shows while recruiting
NCT04571658 is an interventional study that assigns participants to a tested intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, above the 217-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (73% higher).
The record links to 9 conditions, with Focal Segmental Glomerulosclerosis appearing as the primary indexed condition, and to 1 intervention - of which Communication is the first listed.
NCT04571658 lists 16 locations in 12 states (Washington, New York, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT04571658 about?
NCT04571658 is a clinical study titled "NEPTUNE Match Study". NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.
What is the current status of trial NCT04571658?
This trial is currently recruiting. It is a NA study. The enrollment target is 375 participants. The study started on 2022-05-02. Estimated completion is 2029-06-30.
What conditions does trial NCT04571658 study?
This clinical trial studies the following conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy, Alport Syndrome, FSGS.
What interventions are being tested in trial NCT04571658?
The interventions under investigation include: Communication (OTHER).
Who is sponsoring clinical trial NCT04571658?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04571658 being conducted?
This trial has 16 study locations across Georgia, Illinois, Kansas, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Segmental Glomerulosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04571658's enrollment target sits among peer trials
375 3rd of 19 higher than 17 of 19 other Focal Segmental Glomerulosclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Focal Segmental Glomerulosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
RECRUITING · NA
-
taVNS for FRNS in Children
RECRUITING · NA
-
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
RECRUITING · NA
-
A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
RECRUITING · NA
-
Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome
COMPLETED · NA
-
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI